Cancer Research News 26 September 2025

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above

19 October 2025

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can

18 October 2025

Biotechnology · Cancer Research · Healthcare Innovation · Investment News · NASDAQ:GRAL · Stock Market

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics

17 October 2025

Biotechnology · Business News · Cancer Research · Medical Innovations · NASDAQ:GRAL · Stock Market

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with

16 October 2025

Biotechnology · Cancer Research · Health News · NASDAQ:GRAL · Partnerships · Stock Market

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in

16 October 2025

Biotech News · Cancer Research · Investment Insights · Pharma Updates · Stock Market

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial

15 October 2025

Biotech Stocks · Cancer Research · Clinical Trials · Investment Trends · Market News

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 (a personalized cancer vaccine

15 October 2025

Artificial Intelligence · Biotechnology · Cancer Research · Medical Innovation · NASDAQ:EVAX · Stock Market

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Analysis: GRAIL’s stock performance reflects a wave of optimism about its Galleri cancer-screening test and pending trial results. In late September it broke out to new highs, aided by momentum and positive chatter (e.g. a StocksToTrade report noted a 17.93%

3 October 2025

Biotechnology · Cancer Research · Investment News · Medical Innovations · NASDAQ:GRAL · Stock Market

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective

26 September 2025

Biotechnology · Cancer Research · Healthcare · NASDAQ:PSTV · NYSE:UNH · Patient Care · Stock Market

Cancer Research News 26 September 2025 - 19 October 2025